HIV Postexposure Prophylaxis Guidelines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ATLANTA-Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

ATLANTA—Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

Because most occupational HIV exposures do not result in the transmission of HIV, potential toxicity must be carefully considered when prescribing PEP (see Table). Health care personnel with occupational exposure to HIV should receive follow-up counseling, postexposure testing, and medical evaluation, regardless of whether they receive PEP. For management resources, see PEPline (www.ucsf.edu/hivcntr) and Needlestick! (www.needlestick.mednet.ucla.edu).

The basic 2-drug PEP regimens, given for 4 weeks, as recommended in the Table, are zidovudine (Retrovir)/lamivudine (Epivir) (available as Combivir); lamivudine/stavudine (Zerit); and didanosine (Videx)/stavudine.

The expanded 3-drug regimen consists of a basic regimen plus indinavir (Crixivan), nelfinavir (Viracept), efavirenz (Sustiva), or abacavir (Ziagen). Abacavir is available in combination with zidovudine and lamivudine as Trizivir.

Drugs for use as PEP with expert consultation include ritonavir (Norvir), saquinavir (Fortovase), amprenavir (Agenerase), delavirdine (Rescriptor), and lopinavir/ritonavir (Kaletra). 

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content